Vun-Sin Lim, PhD
LightNews LightNews
vslim.bsky.social
Vun-Sin Lim, PhD
@vslim.bsky.social
150 followers 110 following 48 posts
Managing Editor of the Journal of Thoracic Oncology, the official journal of the IASLC.
Posts Replies Media Videos
Pinned
vslim.bsky.social
Vun-Sin Lim, PhD @vslim.bsky.social · Sep 18
#WCLC25 It takes a village!

Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social!

@jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR
vslim.bsky.social
🆕Just published🆕 #LCAM25 Editorial from #JTO Editor-in-Chief Alex Adjei:

"Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal"

🔗 Read the full article here: www.jto.org/article/S155...

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #LCSM
November 5, 2025 at 11:05 AM
vslim.bsky.social
Getting ready for #IASLC Asia Conference on Lung Cancer this week!

Want to know more about #JTO #JTOCRR publications or Reviewer Workshop? Happy to connect in person.

#ACLC25 @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #PeerReview #ScholarlyPublication
October 6, 2025 at 6:24 PM
vslim.bsky.social
#WCLC25 It takes a village!

Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social!

@jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR
September 18, 2025 at 8:54 PM
vslim.bsky.social
#WCLC25 Meet the Editors - Engaging Q&A session between meeting attendees and Editors-in-Chief, Dr Alex Adjei #JTO and Dr Emily Stone #JTOCRR.

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #scholarlypublishing
September 18, 2025 at 7:59 PM
Reposted by Vun-Sin Lim, PhD
drcamidge.bsky.social
kdvr.com/news/health/...
kdvr.com
September 17, 2025 at 1:17 AM
vslim.bsky.social
#JTO & #JTOCRR Editorial Reception

This annual get-together at #WCLC25 lets editors, top reviewers, the editorial office teams and publisher reconnect in person in a meaningful way in the middle of a very busy conference.

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social
September 9, 2025 at 11:58 PM
vslim.bsky.social
#WCLC25 Reviewer Workshop - Here are the next generation of reviewers!

It’s heartwarming to know many attendees came here just for this workshop. A few dedicated participants attended online despite unforeseen circumstances. I’m grateful for all of you, faculty and participants.
@iaslc.bsky.social
September 9, 2025 at 8:41 PM
vslim.bsky.social
#WCLC25 Happening now: IASLC Reviewer Workshop. Alex Adjei - “Top 10 of the do’s and dont’s as a reviewer”

@iaslc.bsky.social @jtoonline.bsky.social #JTO #JTOCFR #peerreview
September 9, 2025 at 9:18 AM
vslim.bsky.social
#WCLC25 Our #JTO editors got many talents!

@drtomjohn.bsky.social @drsanjaypopat.bsky.social @jtoonline.bsky.social @iaslc.bsky.social
drtomjohn.bsky.social Prof Tom John @drtomjohn.bsky.social · Sep 6
Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025
September 6, 2025 at 9:22 AM
Reposted by Vun-Sin Lim, PhD
drtomjohn.bsky.social
Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025
September 6, 2025 at 3:24 AM
vslim.bsky.social
#WCLC25 WS04: Joint IASLC-CSCO-CAALC session happening now in Room 06.

Case presentations and discussions with the panelists with global perspectives.

@iaslc.bsky.social
September 6, 2025 at 7:49 AM
vslim.bsky.social
🆕Special article by Lippman and colleagues in #JTO

📰Press release by UCSD: today.ucsd.edu/story/cancer...

@ucsdcancer.bsky.social @iaslc.bsky.social @sciencedirect.bsky.social @elsevierhms.bsky.social @jtoonline.bsky.social #LCSM
Cancer Breakthrough Sparks New Vaccine
Researchers at UC San Diego and their collaborators have helped answer one of the most difficult questions in oncology: why do some tumors not respond to immunotherapy?
today.ucsd.edu
September 5, 2025 at 9:22 AM
Reposted by Vun-Sin Lim, PhD
alkpositiveuk.bsky.social
Early weight gain as a risk factor for increased maximum weight gain among NSCLC patients on lorlatinib & other ALK tyrosine kinase inhibitors - JTO Clinical and Research Reports.

#LCSM #LungCancer
www.jtocrr.org/article/S266...
July 1, 2025 at 6:57 AM
vslim.bsky.social
✍️June #JTO Editor’s pick 3 of 4: Deuterated Osimertinib

🆓 access: www.jto.org/article/S155...

📎 Also see Deuterated Lorlatinib: www.jto.org/article/S155...
📎 Accompanying editorial: www.jto.org/article/S155...

@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #LCSM
iaslc.bsky.social IASLC @iaslc.bsky.social · Jun 27
Han et al. evaluated 105 patients with advanced EGFR-mutated NSCLC while treating them with TY-9591, a deuterated osimertinib derivative, in this dose-escalation and dose-expansion study. They found that TY-9591 reported favorable safety and substantial efficacy.

Check it out: bit.ly/4dUc2p9
June 27, 2025 at 7:05 PM
vslim.bsky.social
🆕 #JTO Review Article from the #IASLC Basic and Translational Science Committee
🆓 access to full texts 🔗 jto.org/article/S155...

@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lungcancer
June 9, 2025 at 6:47 PM
vslim.bsky.social
🆕 #JTO Review Article from IASLC Advanced Radiation Technology subcommittee

🔗 www.jto.org/article/S155...

#OpenAccess @iaslc.bsky.social @jtoonline.bsky.social @elsevierconnect.bsky.social
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · May 14
Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC)
www.jto.org/article/S155...

The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials
May 14, 2025 at 1:21 PM
Reposted by Vun-Sin Lim, PhD
herbloongmd.bsky.social
Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!
May 7, 2025 at 12:25 PM
vslim.bsky.social
Full support to Alex Adjei for President-Elect in 2025 #IASLC Board of Directors Election!

I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations.
@iaslc.bsky.social
April 19, 2025 at 5:52 PM
vslim.bsky.social
@jtoonline.bsky.social @iaslc.bsky.social #JTO #sclc
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · Mar 11
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study

www.jto.org/article/S155...

The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.
March 28, 2025 at 1:44 AM
Reposted by Vun-Sin Lim, PhD
oncoalert.bsky.social
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study

www.jto.org/article/S155...

The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.
March 11, 2025 at 4:32 PM
Reposted by Vun-Sin Lim, PhD
oncoalert.bsky.social
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)

www.jto.org/article/S155...

These findings suggest that gut microbiota profiling could help optimize treatment strategies for NSCLC.
March 18, 2025 at 2:10 PM
Reposted by Vun-Sin Lim, PhD
hhorinouchi.bsky.social
⏰NOW OUT‼️ #ELCC25
🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS
🎙️Prof. James Yang
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎯Seems like extending the OS for 1️⃣2️⃣ months
✅NCT04487080
#LCSM #EGFR
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social
March 26, 2025 at 5:27 PM
Reposted by Vun-Sin Lim, PhD
tnewsomdavis.bsky.social
MARIPOSA final OS analysis

❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease

❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important

More effective than Osimertinib
Most suitable for higher risk pts

#ELCC25
March 26, 2025 at 4:07 PM
Reposted by Vun-Sin Lim, PhD
iaslc.bsky.social
Congratulations to Keith Kerr, a long-time IASLC member, for receiving the 2025 Heine H Hansen Award at #ELCC2025 👏🏽👏🏽
March 26, 2025 at 1:54 PM
vslim.bsky.social
In January 2025, we joined Taiwan Association for the Study of Lung Cancer (TASLC) in running a reviewer workshop in Taipei. 20 selected participants from Taiwan, Malaysia, Thailand, South Korea & Japan attended the workshop. Thanks TASLC for organizing and support! @jtoonline.bsky.social
March 23, 2025 at 2:35 PM